K. Fatima, Asifa Andleeb, Imtiyaz Hussain, M. Sofi, Afroz Fir, S. Qadri
{"title":"醋酸甲地孕酮治疗癌症恶病质和厌食症:三级护理经验","authors":"K. Fatima, Asifa Andleeb, Imtiyaz Hussain, M. Sofi, Afroz Fir, S. Qadri","doi":"10.4103/jrcr.jrcr_33_21","DOIUrl":null,"url":null,"abstract":"Background: In clinical practice, the management of cancer-related anorexia/cachexia syndrome (CACS) is a great challenge. We conducted an observational study to find the effectiveness and safety of megestrol acetate (MA) for the treatment of CACS. Patients and Methods: One hundred patients of advanced cancer were randomly assigned in the study. Patients received MA 160 mg/oral twice daily. The duration of treatment was 8 weeks. Results: The analysis of the study group demonstrated a statistically significant increase from baseline in body weight (P ≤ 0.01), quality of life (P = 0.02), appetite (P = 0.01), and the Eastern Cooperative Oncology Group performance status (P = 0.03). Conclusion: We concluded that MA is effective and safe in the treatment of CACS.","PeriodicalId":16923,"journal":{"name":"Journal of Radiation and Cancer Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Megestrol acetate in cancer cachexia and anorexia: Tertiary care experience\",\"authors\":\"K. Fatima, Asifa Andleeb, Imtiyaz Hussain, M. Sofi, Afroz Fir, S. Qadri\",\"doi\":\"10.4103/jrcr.jrcr_33_21\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: In clinical practice, the management of cancer-related anorexia/cachexia syndrome (CACS) is a great challenge. We conducted an observational study to find the effectiveness and safety of megestrol acetate (MA) for the treatment of CACS. Patients and Methods: One hundred patients of advanced cancer were randomly assigned in the study. Patients received MA 160 mg/oral twice daily. The duration of treatment was 8 weeks. Results: The analysis of the study group demonstrated a statistically significant increase from baseline in body weight (P ≤ 0.01), quality of life (P = 0.02), appetite (P = 0.01), and the Eastern Cooperative Oncology Group performance status (P = 0.03). Conclusion: We concluded that MA is effective and safe in the treatment of CACS.\",\"PeriodicalId\":16923,\"journal\":{\"name\":\"Journal of Radiation and Cancer Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Radiation and Cancer Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/jrcr.jrcr_33_21\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Radiation and Cancer Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jrcr.jrcr_33_21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Megestrol acetate in cancer cachexia and anorexia: Tertiary care experience
Background: In clinical practice, the management of cancer-related anorexia/cachexia syndrome (CACS) is a great challenge. We conducted an observational study to find the effectiveness and safety of megestrol acetate (MA) for the treatment of CACS. Patients and Methods: One hundred patients of advanced cancer were randomly assigned in the study. Patients received MA 160 mg/oral twice daily. The duration of treatment was 8 weeks. Results: The analysis of the study group demonstrated a statistically significant increase from baseline in body weight (P ≤ 0.01), quality of life (P = 0.02), appetite (P = 0.01), and the Eastern Cooperative Oncology Group performance status (P = 0.03). Conclusion: We concluded that MA is effective and safe in the treatment of CACS.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
